Active, not recruitingPHASE1, PHASE2NCT04455841
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Studying Essential thrombocythemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Corporation
- Principal Investigator
- Amanda McBride, MDIncyte Corporation
- Intervention
- INCB000928(drug)
- Enrollment
- 84 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (30)
- City of Hope National Medical Center, Duarte, California, United States
- City of Hope Orange County, Irvine, California, United States
- Usc Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Stanford Cancer Center, Palo Alto, California, United States
- Prebys Cancer Center, San Diego, California, United States
- Emory University - Winship Cancer Institute, Atlanta, Georgia, United States
- Emory University-Winship Cancer Institute, Atlanta, Georgia, United States
- Start Midwest, Grand Rapids, Michigan, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Weill Cornell Medical Centers, New York, New York, United States
- Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy, Durham, North Carolina, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Md Anderson Cancer Center, Houston, Texas, United States
- Princess Margaret Cancer Center, Toronto, Ontario, Canada
- McGill University Jewish General Hospital, Montreal, Quebec, Canada
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04455841 on ClinicalTrials.govOther trials for Essential thrombocythemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07469891A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPrelude Therapeutics
- RECRUITINGNCT06976918Registry Platform Myelofibrosis and AnemiaiOMEDICO AG
- RECRUITINGNCT07203768A ELN-Multicenter Study on Phenotypic Evolution and Clinical OutcomesFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE2NCT06517875Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisGlaxoSmithKline
- RECRUITINGNANCT06734637Efficacy and Safety of Peginterferon in ET and PV.Zhenya Hong
- RECRUITINGPHASE1NCT06343805A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)Ajax Therapeutics, Inc.
- RECRUITINGPHASE2NCT06541249MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) TrialIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT06552429Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ETXiamen Amoytop Biotech Co., Ltd.